This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Hologic (HOLX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Hologic (HOLX) closed at $72.33, marking a -1.52% move from the previous day.
Why Hologic (HOLX) Could Beat Earnings Estimates Again
by Zacks Equity Research
Hologic (HOLX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Are These Medical Stocks a Great Value Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Hologic's (HOLX) GAI Program to Include Aptima SARS-CoV-2 Assay
by Zacks Equity Research
The addition of Aptima SARS-CoV-2 assay to Hologic's (HOLX) Global Access Initiative is likely to improve its accessibility.
Hologic (HOLX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed at $70.76 in the latest trading session, marking a +0.47% move from the prior day.
Here's Why You Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic (HOLX) given the strength in the diagnostics business and notable acquisition deals.
Hologic (HOLX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed the most recent trading day at $75.09, moving -0.16% from the previous trading session.
Hologic (HOLX) to Meet High Testing Demand With Panther Trax
by Zacks Equity Research
Hologic's (HOLX) Panther Trax scalable solutions will meet the needs of today's laboratories, enabling them to expand operational capacity and testing volumes.
Hologic (HOLX) Stock Moves -0.68%: What You Should Know
by Zacks Equity Research
In the latest trading session, Hologic (HOLX) closed at $77.18, marking a -0.68% move from the previous day.
Hologic (HOLX) Stock Moves -0.74%: What You Should Know
by Zacks Equity Research
In the latest trading session, Hologic (HOLX) closed at $74.83, marking a -0.74% move from the previous day.
Hologic (HOLX) Reports New Findings on Breast Cancer Index
by Zacks Equity Research
Hologic's (HOLX) latest data on Breast Cancer Index demonstrates its effectiveness in predicting net benefit from extended endocrine therapy.
Hologic (HOLX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Hologic (HOLX) closed at $76.05, marking a -0.13% move from the previous day.
Hologic (HOLX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed at $73.77 in the latest trading session, marking a +0.97% move from the prior day.
Hologic (HOLX) Up 5.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hologic (HOLX) Q4 Earnings Surpass Estimates, 2022 View Dull
by Zacks Equity Research
Impressive performance by the Breast Health and GYN Surgical segments drives Hologic's (HOLX) fiscal fourth-quarter revenues.
Hologic (HOLX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 64.29% and 29.14%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Breast Health Sales to Drive Hologic's (HOLX) Q4 Earnings
by Zacks Equity Research
The acquisition of Biotheranostics and the launch of new software are expected to have contributed to Hologic's (HOLX) Breast Health arm performance in the fourth quarter.
Hologic (HOLX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Hologic's (HOLX) recent acquisitions and product launches are expected to contribute significantly to its fourth-quarter performance.
Hologic (HOLX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed the most recent trading day at $73.03, moving -0.79% from the previous trading session.
Analysts Estimate Hologic (HOLX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Hologic (HOLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hologic (HOLX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed at $70.02 in the latest trading session, marking a +0.5% move from the prior day.
Hologic (HOLX) to Expand Surgical Portfolio With Bolder Buyout
by Zacks Equity Research
Hologic's (HOLX) recent acquisition will accelerate its growth and enhance patient outcomes by leveraging significant commercial resources and strong relationships with OB/GYN specialists.
BD's (BDX) New Manufacturing Facility to Boost Supply Readiness
by Zacks Equity Research
BD's (BDX) latest manufacturing line is expected to not only boost supply capacity but also provide priority access to needles and syringes to the U.S. government.
Hologic (HOLX) Launches Novodiag System for On-Demand Testing
by Zacks Equity Research
Hologic (HOLX) introduces the Novodiag system in Europe for on-demand testing of infectious diseases and antimicrobial resistance.
Thermo Fisher (TMO) Boosts COVID Testing With Wastewater Kit
by Zacks Equity Research
Thermo Fisher's (TMO) wastewater surveillance method is set to identify asymptomatic carriers on college campuses to monitor regional spread among communities.